Avacta Group Plc

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:05:07 12/02/2026 pm IST			5-day change	1st Jan Change
58.50 ^GBX	-1.68%		-2.50%	+0.86%

09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Names Chemistry Vice President as Chief Scientific Officer	MT

Avacta Therapeutics' AVA6000 Phase 1a Dose Escalation Shows Early Efficacy

Published on 03/07/2025 at 03:10 pm IST

Reuters

Latest news about Avacta Group Plc

09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Names Chemistry Vice President as Chief Scientific Officer	MT
09/02	Avacta Therapeutics Announces Executive Changes	CI
04/02	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta Group Updates Trial Protocol in Faridoxorubicin Program	MT
03/02	Avacta Therapeutics says cardiac dosing limit removed in Faridoxorubicin program	RE
21/01	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
21/01	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
21/01	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
21/01	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT
20/01	EARNINGS AND TRADING: Treatt cuts dividend after "challenging year"	AN
18/12	Avacta Reports New Pharmacology Data for Fap-Exd	CI
18/12	Avacta Group Plc - Special Call
18/12	Avacta Therapeutics Announces Faridoxorubicin Phase 1B Cohort Demonstrates Clinically Meaningful Tumor Shailage in Patients with Salivary Metals Cancer	CI
17/12	Avacta says salivary gland cancer drug shrinks tumour	AN
17/12	Avacta's Salivary Gland Cancer Therapy Shows Efficacy in Early-stage Study	MT
08/12	Avacta to announce initial phase 1b data on faridoxorubicin	AN
03/11	Avacta Therapeutics Finalizes Share Placing, Convertible Bond Amendments	MT
25/25/25	Avacta Presents First Preclinical Data from Dual Payload Pre\|Cision® Medicines At the 2025 Aacr-Nci-Eortc International Conference on Molecular Targets	CI
20/25/20	Avacta hails data for faridoxorubicin to treat salivary gland cancers	AN
20/25/20	Avacta Group Raises GBP16 Million via Share Placement	MT
19/25/19	Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre\|CISION®? Platform at the European Society of Medical Oncology Annual Congress	CI
02/25/02	Avacta Group Plc, H1 2025 Earnings Call, Sep 30, 2025

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Employees

151

Sector

Biotechnology & Medical Research

Calendar

16/04 - Q4 2025 Earnings Release (Projected)

More about the company